{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:22:58Z","timestamp":1778660578859,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"am","delay-in-days":358,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA030206"],"award-info":[{"award-number":["P01 CA030206"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA033572"],"award-info":[{"award-number":["P30 CA033572"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clml.2023.05.011","type":"journal-article","created":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T02:48:33Z","timestamp":1684810113000},"page":"e268-e276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1109-6955","authenticated-orcid":false,"given":"Matthew","family":"Mei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joycelynne","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole Ni-Chun","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"O'Hearn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Forman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Spielberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji-Lian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6650-5704","authenticated-orcid":false,"given":"Myo","family":"Htut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monzr M.","family":"Al Malki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Auayporn","family":"Nademanee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2023.05.011_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1705008","article-title":"The graft-versus-lymphoma effect: clinical review and future opportunities","volume":"36","author":"Butcher","year":"2005","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.clml.2023.05.011_bib0002","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.bbmt.2006.08.035","article-title":"Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma","volume":"12","author":"Rodriguez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2023.05.011_bib0003","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood-2007-07-098483","article-title":"Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia","volume":"111","author":"Sorror","year":"2008","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2023.05.011_bib0004","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Lymphoma working committee of the C. Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2023.05.011_bib0005","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/j.1365-2141.2009.07905.x","article-title":"Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"147","author":"Avivi","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2023.05.011_bib0006","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bbmt.2014.02.009","article-title":"Pretransplantation fluorine-18-deoxyglucose: positron emission tomography scan lacks prognostic value in chemosensitive B cell non-hodgkin lymphoma patients undergoing nonmyeloablative allogeneic stem cell transplantation","volume":"20","author":"Sauter","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"10.1016\/j.clml.2023.05.011_bib0007","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1002\/cncr.25357","volume":"116","author":"Dodero","year":"2010","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clml.2023.05.011_bib0008","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1148\/radiol.2015142556","article-title":"Prognostic Value of FDG PET\/CT before allogeneic and autologous stem cell transplantation for aggressive lymphoma","volume":"277","author":"Ulaner","year":"2015","journal-title":"Radiology"},{"issue":"4","key":"10.1016\/j.clml.2023.05.011_bib0009","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000368291","article-title":"Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant","volume":"133","author":"Arnason","year":"2015","journal-title":"Acta Haematol"},{"issue":"2","key":"10.1016\/j.clml.2023.05.011_bib0010","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/leu.2016.305","article-title":"Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499","volume":"31","author":"Smith","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2023.05.011_bib0011","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14737140.2.5.485","article-title":"Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma","volume":"2","author":"Grillo-L\u00f3pez","year":"2002","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.clml.2023.05.011_bib0012","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/ejh.13138","article-title":"(90) Y-ibritumomab-tiuxetan as a therapeutic alternative for follicular lymphoma (FL): a single-center experience","volume":"101","author":"Spukti","year":"2018","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2023.05.011_bib0013","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","article-title":"Phase II trial of a transplantation regimen of 90yttrium ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma","volume":"26","author":"Krishnan","year":"2008","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2023.05.011_bib0014","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1158\/1078-0432.CCR-17-3561","article-title":"Updated results of rituximab pre- and post-BEAM with or without 90yttrium ibritumomab tiuxetan during autologous transplant for diffuse large B-cell lymphoma","volume":"24","author":"Chahoud","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.clml.2023.05.011_bib0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/10428190500260478","article-title":"Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan","volume":"47","author":"Fietz","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2023.05.011_bib0016","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/sj.bmt.1705919","article-title":"Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma","volume":"41","author":"Shimoni","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.clml.2023.05.011_bib0017","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1182\/blood-2010-02-270538","article-title":"Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study","volume":"116","author":"Bethge","year":"2010","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.clml.2023.05.011_bib0018","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/bmt.2010.339","article-title":"90Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma","volume":"46","author":"Abou-Nassar","year":"2011","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.clml.2023.05.011_bib0019","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1182\/blood-2010-12-324392","article-title":"\u2079\u2070Y-ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma","volume":"118","author":"Gopal","year":"2011","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2023.05.011_bib0020","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1182\/blood-2012-03-417808","article-title":"Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results","volume":"119","author":"Khouri","year":"2012","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2023.05.011_bib0021","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1016\/j.bbmt.2018.06.033","article-title":"Long-term follow-up of 90Y-ibritumomab tiuxetan, fludarabine, and total body irradiation-based nonmyeloablative allogeneic transplant conditioning for persistent high-risk B cell lymphoma","volume":"24","author":"Puronen","year":"2018","journal-title":"Biol Blood Marrow Trans"},{"issue":"9","key":"10.1016\/j.clml.2023.05.011_bib0023","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/sj.bmt.1705801","article-title":"Reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation with fludarabine and melphalan is associated with durable disease control in myelodysplastic syndrome","volume":"40","author":"Nakamura","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2023.05.011_bib0024","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bbmt.2009.09.020","article-title":"Improved outcomes using tacrolimus\/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis","volume":"16","author":"Snyder","year":"2010","journal-title":"Biol Blood Marrow Trans"},{"issue":"9","key":"10.1016\/j.clml.2023.05.011_bib0025","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/j.bbmt.2018.04.029","article-title":"Melphalan-based reduced-intensity conditioning is associated with favorable disease control and acceptable toxicities in patients older than 70 with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation","volume":"24","author":"Al Malki","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.clml.2023.05.011_bib0026","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2023.05.011_bib0027","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.clml.2023.05.011_bib0028","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"10","key":"10.1016\/j.clml.2023.05.011_bib0029","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","article-title":"Regimen-related toxicity in patients undergoing bone marrow transplantation","volume":"6","author":"Bearman","year":"1988","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2023.05.011_bib0030","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdu503","article-title":"90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas","volume":"26","author":"Bouabdallah","year":"2015","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.clml.2023.05.011_bib0031","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/bmt.2012.62","article-title":"Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma","volume":"47","author":"Bethge","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2023.05.011_bib0032","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.bbmt.2016.10.003","article-title":"Phase II study of yttrium-90-ibritumomab tiuxetan as part of reduced-intensity conditioning (with melphalan, fludarabine +\/- thiotepa) for allogeneic transplantation in relapsed or refractory aggressive B cell lymphoma: a GELTAMO trial","volume":"23","author":"Cabrero","year":"2017","journal-title":"Biol Blood Marrow Trans"},{"issue":"1","key":"10.1016\/j.clml.2023.05.011_bib0033","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/bloodadvances.2021005056","article-title":"Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma","volume":"6","author":"Chow","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.clml.2023.05.011_bib0034","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbmt.2018.09.009","article-title":"Outcomes of patients with recurrent and refractory lymphoma undergoing allogeneic hematopoietic cell transplantation with BEAM Conditioning and sirolimus- and tacrolimus-based GVHD prophylaxis","volume":"25","author":"Salhotra","year":"2019","journal-title":"Biol Blood Marrow Trans"},{"issue":"9","key":"10.1016\/j.clml.2023.05.011_bib0035","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.leukres.2012.04.022","article-title":"Reduced intensity allogeneic hematopoietic stem cell transplantation for MDS using tacrolimus\/sirolimus-based GVHD prophylaxis","volume":"36","author":"Nakamura","year":"2012","journal-title":"Leuk Res"},{"issue":"27","key":"10.1016\/j.clml.2023.05.011_bib0036","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","article-title":"Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy","volume":"25","author":"Czuczman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.05.011_bib0037","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-19-2856","article-title":"Ibrutinib treatment for first-line and relapsed\/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase 1b\/2 PCYC-1102 study","author":"Byrd","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.clml.2023.05.011_bib0038","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1038\/s41375-019-0575-9","article-title":"Dlugosz-Danecka M. Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma","volume":"33","author":"Wang","year":"2019","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2023.05.011_bib0039","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/blood-2018-10-879643","article-title":"Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy","volume":"134","author":"Zucca","year":"2019","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.clml.2023.05.011_bib0040","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.clml.2023.05.011_bib0041","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2023.05.011_bib0042","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clml.2023.05.011_bib0043","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D\u2019Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2023.05.011_bib0044","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10254","key":"10.1016\/j.clml.2023.05.011_bib0045","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clml.2023.05.011_bib0046","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematologica"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:49Z","timestamp":1761871369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2152265023001696"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.05.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}